Navicixizumab (Anti-DLL4)
Product Specifications
CAS Number
1638338-43-8
Synonyms
OMP-305B83; Anti-DLL4 Reference Antibody
Additionnal Information
Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb1607671 100 µL
Phospho-PKC delta (Tyr311) Rabbit Polyclonal Antibody (BF488)
Sign In for Pricing
View Details